

MBF-118
MBF-118 is a potent and selective, covalent, partial agonist of the PPARγ nuclear receptor as a potential therapy for fibrostenosing Crohn’s disease (FSCD)
MBF-118 has completed a phase IIa PoC trial in FSCD
MBF-362
MBF-362 is an antagonist of the prostaglandin EP4 receptor as a novel non-hormonal therapy for endometriosis
MBF-362 also completed a phase Ib trial for solid tumours
MBF-015
MBF-015 is a novel and selective HDAC1/2 inhibitor as a potential disease modifying therapy for synaptic loss in neurodegenerative diseases
MBF-015 has completed a phase IIa PoC trial in Huntington’s disease

